Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Trial Profile

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Anorexia; Cachexia
  • Focus Registrational; Therapeutic Use
  • Acronyms ROMANA-1
  • Sponsors Helsinn Therapeutics
  • Most Recent Events

    • 02 Jun 2017 Results of post-hoc pooled analysis (n=829) of two pivotal trials (ROMANA 1 and ROMANA 2) assessing the body weight response with anamorelin, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 Oct 2016 Results of pooled, post hoc analysis of ROMANA 1 (NCT01387269; N = 484) and ROMANA 2 (NCT01387282; N = 495) presented at the 41st European Society for Medical Oncology Congress
    • 07 Jun 2016 Results (post-hoc pooled analysis of this and other study, n = 829) assessing response to anamorelin specifically in patients with BMI below 20 kg/m2 presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top